Previous 10 | Next 10 |
Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024 PR Newswire SECAUCUS, N.J. , Jan. 17, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information ser...
Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health PR Newswire Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage...
2024-01-16 11:49:56 ET More on iShares Russell 1000 Growth ETF: IWF: Price Isn't Everything; Favor Growth Over Value Citi’s 30 stocks for its 2024 top themes Top overweight stocks with high growth and low volume - MS Seeking Alpha’s Quant Rating...
2024-01-15 08:00:15 ET Quest Diagnostics, Inc. (DGX) declaring a stock dividend of $0.71 per share on Ex-Date : January 16, 2024. Shareholders on record as of January 17, 2024 are eligible for the dividend. The payment date is scheduled for January 31, 2024, and the declaration was ...
2024-01-09 09:41:19 ET More on Quest Diagnostics Quest Diagnostics: Market Overreaction Creates Investment Opportunity Quest Diagnostics: Moving Past Covid Quest Diagnostics Inc. (DGX) Q3 2023 Earnings Call Transcript BofA raises Quest to buy, calls it "growt...
Goal to combine Ultima’s highly sensitive, low-cost technology with Quest’s oncology expertise and national scale in order to improve patient access, affordability and outcomes Ultima Genomics , a developer of a revolutionary new ultra-high throughput sequencing archit...
Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System PR Newswire Transaction to broaden access to innovative, quality diagnostic information services for providers and patients SECAUCUS, N.J. , Jan. 8, 2024 ...
Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC PR Newswire BALTIMORE , Jan. 8, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX)...
2024-01-08 03:40:52 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...
NORTHAMPTON, MA / ACCESSWIRE / January 4, 2024 / Quest Diagnostics recently provided no-cost Blueprint for Wellness® testing to more than 100 local community members who attended a wellness day in the Mississippi Delta region. The ninth annual I-HEAL Community Wellness Day, hosted by Quest ...
News, Short Squeeze, Breakout and More Instantly...
Quest Diagnostics Incorporated Company Name:
DGX Stock Symbol:
NYSE Market:
Quest Diagnostics Incorporated Website:
Haystack Oncology and Université de Montréal's affiliated hospital research centre, the CRCHUM, to Deploy Haystack MRD™ Technology in Research Study for Metastatic Colorectal Cancer PR Newswire BALTIMORE, Md. and MONTREAL , July 29, 2024 /PRN...
BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases PR Newswire Collaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care FRANKLIN LAKES, N.J. and SECAUCUS, N.J. , July 25, 20...
2024-07-24 07:00:10 ET Eric Coldwell from Robert W. Baird issued a price target of $154.00 for DGX on 2024-07-24 06:36:00. The adjusted price target was set to $154.00. At the time of the announcement, DGX was trading at $140.96. The overall price target consensus is at ...